
Formation Bio
Formation Bio is a tech-driven, AI-native pharmaceutical company revolutionizing drug development. By leveraging a proprietary technology platform, they expedite the development of treatments, aiming to meet critical unmet patient needs efficiently without compromising quality or safety. They acquire clinical-stage drugs from various sources and enhance their development process to achieve faster inflection points than industry norms. Their multidisciplinary team combines extensive expertise in drug selection, development, and technology, having collectively worked on over 45 approved drugs, ensuring a robust and innovative approach to bringing new treatments to patients.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
Company valuation calculator
To calculate, specify one of the parameters
News related to Formation Bio16
Formation BioFormation Bio Announces $600 Million Debut Fund to Expand Drug ...
PRNewswire/ -- Formation Bio, an AI-native pharmaceutical company, today announced the Formation Bio Drug Development Accelerator Fund (the "Fund"), ...
https://www.prnewswire.com/news-releases/formation-bio-announces-600-million-debut-fund-to-expand-drug-development-capacity-302921852.html
Formation BioFormation Bio's AI-ready repository of knowledge - Fast Company
Formation Bio used AI to make its vast trove of data more readily available to employees, landing the company at No. 7 on Best Workplaces for Innovators ...
https://www.fastcompany.com/91591991/formation-bio-best-workplaces-for-innovators-2026
Formation BioFormer Biogen Executive to Lead Research at Formation Bio
Formation Bio said it has appointed former Biogen Inc. research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech ...
https://www.bloomberg.com/news/articles/2026-07-22/former-biogen-executive-to-lead-research-at-formation-bio
Formation BioFormation Bio Appoints Michael Ehlers as Chief Scientific Officer ...
PRNewswire/ -- Formation Bio, an AI-native pharma company, today announced the appointment of Michael D. Ehlers, MD, PhD, as Chief Scientific Officer (CSO)....
https://www.prnewswire.com/news-releases/formation-bio-appoints-michael-ehlers-as-chief-scientific-officer-and-head-of-rd-302831565.html
Formation BioLynk Pharmaceuticals' Partner Formation Bio Doses First Participant ...
Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 ...
https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-partner-formation-bio-doses-first-participant-in-phase-1-trial-of-blkr201-originally-designated-as-lnk01006-a-cns-penetrant-tyk2-inhibitor-302795367.html
Show more (11)Investors3
Andreessen Horowitz
Sequoia Capital
Thrive Capital